(lp0
S"Peregrine Pharmaceuticals : What's Next? Insider Financial - Mar 14, 2017 Our regular readers will be more than aware by now that Peregrine Pharmaceuticals  is a company we keep on coming back to.Company Update : Peregrine Pharmaceuticals Announces Financial ... - Smarter AnalystPeregrine Pharmaceuticals'  CEO Steve King on Q3 2017 Results - Earnings ... - Seeking Alpha"
p1
aS'Why to Keeping Eye on Tidewater Inc. , Peregrine Pharmaceuticals, Inc ... StockNewsJournal - 15 hours ago Peregrine Pharmaceuticals, Inc. , at its latest closing price of $0.72, it has a price-to-book ratio of 4.81, compared to an industry average at 4.12.The Peregrine Pharmaceuticals  Stock Rating Upgraded by Zacks Investment ... - Petro Global News 24Its time to give a fresh look to Peregrine Pharmaceuticals, Inc.  and ... - USA Commerce Daily'
p2
aS"Today's Research Reports on Trending Biotech Tickers: Peregrine ... Yahoo Finance - Mar 9, 2017 Peregrine Pharmaceuticals' shares declined 1.86 percent to close at $0.68 a share on Wednesday. The stock traded between $0.65 and $0.69 on volume of 3.18 million shares traded."
p3
aS'Peregrine Pharmaceuticals  Is One To Watch Ahead Of Earnings Insider Financial - Mar 6, 2017 Our more regular readers will know that Peregrine Pharmaceuticals  is one of the stocks we visit regularly. The company - as we have stated in the past, and an opinion that still stands - is one of the most mis-valued/misunderstood ...Peregrine Pharmaceuticals Inc.: Peregrine to Report Financial Results for ... - The Wall Street TranscriptPeregrine Pharmaceuticals, Inc.  in-depth technical analysis - Post Analyst'
p4
aS'Ronin Capital Shows New 6.8% Stake in Peregrine Pharmaceuticals  - 13D StreetInsider.com - Mar 2, 2017 Stephen White is the indirect beneficial owner of all of the securities of Peregrine Pharmaceuticals, Inc. held of record or beneficially owned by SW Investment Management LLC by virtue of his having sole voting and dispositive power over such shares.Is Peregrine Pharmaceuticals, Inc.  Preparing For A Breakout Trade? - Post AnalystInvestor Research Report on Peregrine Pharmaceuticals, Inc.  - FactsReporter'
p5
aS"BRIEF-Peregrine Pharmaceuticals Q3 loss per share $0.04 Reuters - Mar 13, 2017 Reuters is the news and media division of Thomson Reuters. Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news&nbsp;..."
p6
aS"PEREGRINE PHARMACEUTICALS, INC.  Files An 8-K Other Events Market Exclusive - Mar 9, 2017 Peregrine Pharmaceuticals, Inc.  is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which&nbsp;...What's Happening To These Stocks?  Peregrine Pharmaceuticals, Inc. (PPHM ... - Post Analyst"
p7
aS'Analysts Near-Term outlook: the Rubicon Project, Inc. , Peregrine ... The USA Commerce - Mar 21, 2017 The share price is now down -29.40% for the past three months. Latest closing price was -32.43% below its 50-day moving average and -41.11% below its 200-day moving average.'
p8
aS"What Does The Chart For Peregrine Pharmaceuticals, Inc.  Tell Us Presently? NY Stock News - 16 hours ago Peregrine Pharmaceuticals, Inc.  has presented a rich pool of technical data in recent sessions. These are the trends we've been tracking and how we feel they should be played in the current environment."
p9
aS'Stock Under Limelight: Peregrine Pharmaceuticals, Inc.  The Oracle Examiner - 15 hours ago Currently Peregrine Pharmaceuticals, Inc.  is showing beta of 2.05. This particular value of beta suggests that Peregrine Pharmaceuticals, Inc.  has historically moved 205% for every 100% move in the benchmark, based on price level.'
p10
a.